Open AccessCrispr Library Screening: Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma (Adv. Sci. 17/2019)
Author(s) -
Huang Kai,
Liu Xing,
Li Yansheng,
Wang Qixue,
Zhou Junhu,
Wang Yunfei,
Dong Feng,
Yang Chao,
Sun Zhiyan,
Fang Chuan,
Liu Chaoyong,
Tan Yanli,
Wu Xudong,
Jiang Tao,
Kang Chunsheng
Publication year - 2019
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.201970103
Subject(s) - crispr , temozolomide , glioblastoma , cas9 , genome , computational biology , genetics , gene , biology , cancer research
In article number 1900782, Xudong Wu, Tao Jiang, and Chunsheng Kang, and co‐workers present a genome‐wide screening under a clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 library. Notably, E2F6 was proven to drive the temozolomide (TMZ) resistance of 191 glioblastoma‐related candidate genes. To silence the expression of E2F6 is a promising strategy to conquer TMZ resistance in glioblastoma.